LUND, Sweden,
Oct. 26, 2018 /PRNewswire/ -- The
Nomination Committee, which is to be appointed for the period until
a new Nomination Committee has been appointed, will have four
members, of which three will be appointed by the three largest
shareholders of the company in terms of votes, and the fourth will
be the Chairman of the Board. In cases where the Chairman of the
Board is one of the three largest shareholders, in his/her capacity
as shareholder, the Chairman will put his/her place at the disposal
of the Committee, and the next-largest shareholder will be offered
the entitlement to appoint a member of the Nomination Committee. As
soon as reasonably possible after the end of the third quarter, the
Chairman of the Board should contact the three largest shareholders
in terms of votes recorded in the share register maintained by
Euroclear Sweden AB and request that within a reasonable time in
the circumstances, although not more than 30 days, they state the
name of the individual such shareholder wishes to appoint as a
member of the Nomination Committee. If one of the three largest
shareholders does not wish to exercise its entitlement to appoint a
member of the Nomination Committee, the next shareholder in turn
will be offered the entitlement to appoint a member of the
Nomination Committee. In the case where several shareholders
decline their entitlement to appoint members of the Nomination
Committee, the Chairman of the Board should not need to contact
more than eight shareholders, unless this is necessary to compose a
Nomination Committee of at least three members.
Unless otherwise agreed between the members, that member
appointed by the largest shareholder in terms of votes will be
appointed Chairman of the Nomination Committee. The Chairman of the
Board or other Director may never serve as Chairman of the
Nomination Committee.
Based on the above, the nomination committee have for the 2019
AGM been determined to consist of the following persons whom
together represent approximately 25 percent of the number of shares
and votes in the Company per September
30 2018:
- Sara Ek, representing
Sara Ek, Chairman of the Nomination
Committee
- Carl Borrebaeck representing Carl Borrebaeck, Chairman of the
Board
- Mikael Löfman representing Mikael Löfman; and
- Astrid Samuelsson, representing
Handelsbanken
The suggestion from the nomination committee will be presented
in the notice to the AGM 2019 as well as on the Company website,
www.immunovia.com.
Shareholders who wish to leave suggestions to the nomination
committee are welcome to contact the nomination committee at the
Company address. In order for the nomination committee to take a
suggestion into account, the suggestion must have been received in
a timely manner before the AGM, January
31 2019 at the latest.
For more information, please contact:
Mats
Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out above.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/immunovia-ab--publ--nomination-committee-appointed-for-agm-2019,c2656573
The following files are available for download:
http://mb.cision.com/Main/13121/2656573/933993.pdf
|
Immunovia PR,
nomination committee 2019
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-ab-publ-nomination-committee-appointed-for-agm-2019-300738573.html
SOURCE Immunovia AB